AllerGenis utilizes predictive data analytics for the detection and management of life-threatening immune response disorders. Amassing the world’s largest database of phenotypic patient data, the company is leading the field in developing precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. The company was founded out of a collaboration with Hugh Sampson MD, of the Icahn School of Medicine at Mount Sinai. Mount Sinai Health System has licensed its proprietary epitope mapping platform to AllerGenis, which the company is using to create the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and clinical outcomes to gain meaningful insights.
Diagnosis of food allergy can be quite cumbersome. Screening tests like skin prick tests and serology determination of IgE antibodies specific to foods are the only measure of the sensitization to foods supporting clinicians in the diagnostic workflow. While the gold standard for diagnosis remains the oral food challenge (OFC), a novel diagnostic, the Basophil Activation Test (BAT), is a standardized in vitro induction of the allergic reaction in a patients collected basophils and is reported to reproduce a patient’s allergic reaction in a safe blood test (Scott et al., 2017). Compared to the in vivo OFC, the in vitro BAT assay bears much less risk to the patient and overall cost. (Duan et al., 2021).
BUHLMANN Diagnostics Corp (BDC), the North American affiliate of BÜHLMANN Laboratories AG, offers in vitro ‘Allergy in a Vial’, with our Flow CAST® BAT assay in combination with a broad range of quality, standardized and validated allergens. These include controlled food allergens, food additive allergens, environmental allergens, inhalant and drug allergens. In addition to BAT testing, BUHLMANN offers unique assays for Gastroenterology, Neuroimmunology, Point of Care and Clinical Chemistry. Flow CAST® is for Research Use Only in the United States.
FARE is the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. FARE is transforming the future of food allergy through innovative initiatives that will lead to increased awareness, new and improved treatments and prevention strategies, effective policies and legislation and novel approaches to managing the disease.
To learn more about FARE, visit our Living Teal™ YouTube channel, or www.foodallergy.org